%0 Journal Article
%T New research in testicular cancer, ASCO-GU 2017
%J Archive of "Canadian Urological Association Journal".
%D 2017
%R 10.5489/cuaj.4609
%X At the American Society of Clinical Oncology 2017 Genitourinary Cancers Symposium, researchers presented the results of a single-arm trial investigating the efficacy of a single cycle of bleomycin, etoposide, and cisplatin (BEP) as adjuvant chemotherapy for high-risk, stage 1, non-seminomatous or combined germ cell tumours of the testis (NSGCTT).1 The 236 subjects received one cycle of BEP, with etoposide dosed at 165mg/m2 Day 1¨C3 and cisplatin 50 mg/m2 Days 1 and 2. They were followed for five years post-orchiectomy. The primary efficacy endpoint was malignant recurrence at two years, defined as active undifferentiated disease ¡À rising markers, multiple site relapse. Teratoma differentiated recurrence was a secondary endpoint
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461156/